New Delhi, Dec 11 (IANS) In a significant medical feat, Indian scientists have developed the first-in-human gene therapy using lentiviral vectors for severe haemophilia A
The innovative therapy, developed by the Centre for Stem Cell Research (CSCR) at Christian Medical College (CMC), Vellore — a translational unit of BRIC-inStem, and supported by the Department of Biotechnology, has demonstrated transformational results.
Early this year, scientists at the CMC-Vellore successfully conducted the country’s first human clinical trial of gene therapy for haemophilia A (FVIII deficiency).
The single-centre study, which enrolled five participants aged between 22 and 41 years, showed transformational results.
“The therapy successfully produced zero annualised bleeding rates in all five enrolled participants while enabling prolonged production of Factor VIII, eliminating the need for repeated infusions,” said the scientists, in the paper published in the peer-reviewed New England Journal of Medicine.
This effect was observed “over a cumulative follow-up of 81 months, correlating Factor VIII activity with vector copy numbers in the peripheral blood,” the team said.
Haemophilia A is a severe bleeding disorder caused by the deficiency of clotting Factor VIII. It significantly affects patients’ quality of life, leading to spontaneous bleeding episodes. Although rare, India bears the world’s second-largest burden of haemophilia, with approximately 136,000 cases.
Current treatments require frequent Factor VIII replacement therapy, which faces challenges such as high costs, venous access in children, and low patient acceptance.
The new gene therapy approach involves the use of a lentiviral vector to introduce a normal copy of the Factor VIII gene into autologous haematopoietic stem cells (HSCs).
These modified HSCs generate blood cells capable of producing functional Factor VIII over extended periods.
“Participants were monitored for six months following the gene therapy. Results showed a strong correlation between Factor VIII activity levels and the vector copy number in peripheral blood,” the researchers said.
“This achievement underscores the long-term efficacy and safety of the therapy, offering renewed hope for patients with severe Haemophilia A,” they added.
This pioneering study marks a transformative leap in accessible and effective treatments for resource-limited settings, unlocking new possibilities for managing previously incurable diseases. The therapy is expected to soon undergo a second phase human trial.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
